ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes

TUESDAY, April 9, 2024 -- Semaglutide leads to larger reductions in heart failure-related symptoms and physical limitations among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news